Ferragud Antonio, Howell Adam D, Moore Catherine F, Ta Tina L, Hoener Marius C, Sabino Valentina, Cottone Pietro
Laboratory of Addictive Disorders, Departments of Pharmacology and Experimental Therapeutics and Psychiatry, Boston University School of Medicine, Boston, MA, USA.
Graduate Program for Neuroscience, Boston University School of Medicine, Boston, MA, USA.
Neuropsychopharmacology. 2017 Jun;42(7):1458-1470. doi: 10.1038/npp.2016.233. Epub 2016 Oct 6.
Compulsive, binge eating of highly palatable food constitutes a core feature of some forms of obesity and eating disorders, as well as of the recently proposed disorder of food addiction. Trace amine-associated receptor 1 (TAAR1) is a highly conserved G-protein-coupled receptor bound by endogenous trace amines. TAAR1 agonists have been shown to reduce multiple behavioral effects of drugs of abuse through their actions on the mesocorticolimbic system. In this study, we hypothesized that TAAR1 may have a role in compulsive, binge-like eating; we tested this hypothesis by assessing the effects of a TAAR1 agonist, RO5256390, in multiple excessive feeding-related behaviors induced by limiting access to a highly palatable diet in rats. Our results show that RO5256390 blocked binge-like eating in rats responding 1 h per day for a highly palatable sugary diet. Consistent with a palatability-selective effect, drug treatment selectively reduced the rate and regularity of palatable food responding, but it did not affect either baseline intake or food restriction-induced overeating of the standard chow diet. Furthermore, RO5256390 fully blocked compulsive-like eating when the palatable diet was offered in an aversive compartment of a light/dark conflict box, and blocked the conditioned rewarding properties of palatable food, as well as palatable food-seeking behavior in a second-order schedule of reinforcement. Drug treatment had no effect on either anxiety-like or depressive-like behavior, and it did not affect control performance in any of the tests. Importantly, rats exposed to palatable food showed decreased TAAR1 levels in the medial prefrontal cortex (mPFC), and RO5256390 microinfused into the infralimbic, but not prelimbic, subregion of the mPFC-reduced binge-like eating. Altogether, these results provide evidence for TAAR1 agonism as a novel pharmacological treatment for compulsive, binge eating.
强迫性地大量进食美味食物是某些形式的肥胖症、饮食失调以及最近提出的食物成瘾症的一个核心特征。痕量胺相关受体1(TAAR1)是一种高度保守的G蛋白偶联受体,可与内源性痕量胺结合。TAAR1激动剂已被证明可通过作用于中脑皮质边缘系统来减少滥用药物的多种行为效应。在本研究中,我们假设TAAR1可能在强迫性、暴饮暴食样进食中起作用;我们通过评估TAAR1激动剂RO5256390对大鼠因限制获取美味食物而引发的多种与过度进食相关行为的影响来验证这一假设。我们的结果表明,RO5256390可阻止每天仅能获取1小时美味含糖饮食的大鼠出现暴饮暴食样进食行为。与适口性选择性效应一致,药物治疗选择性地降低了对美味食物反应的速率和规律性,但并未影响标准普通饮食的基线摄入量或食物限制诱导的暴饮暴食。此外,当在明暗冲突箱的厌恶隔间提供美味食物时,RO5256390可完全阻止强迫样进食,并阻断美味食物的条件性奖赏特性以及二级强化程序中的美味食物寻求行为。药物治疗对焦虑样或抑郁样行为均无影响,且在任何测试中均不影响对照表现。重要的是,接触美味食物的大鼠内侧前额叶皮质(mPFC)中的TAAR1水平降低,而向mPFC的下缘而非前边缘亚区域微量注射RO5256390可减少暴饮暴食样进食。总之,这些结果为TAAR1激动剂作为强迫性暴饮暴食的新型药物治疗提供了证据。